🇺🇸 FDA
Pipeline program

CHF5993 pMDI (100) -152a, CHF5993 pMDI HFA-152a, Trimbow 87 micrograms/5 micrograms/9 micrograms pressurised inhalation, solution

CLI-05993AA9-01

Phase 2 small_molecule active

Quick answer

CHF5993 pMDI (100) -152a, CHF5993 pMDI HFA-152a, Trimbow 87 micrograms/5 micrograms/9 micrograms pressurised inhalation, solution for Mild to moderate asthma is a Phase 2 program (small_molecule) at Chiesi Farmaceutici S.p.A with 1 ClinicalTrials.gov record(s).

Program details

Company
Chiesi Farmaceutici S.p.A
Indication
Mild to moderate asthma
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials